Equities analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post $866.57 million in sales for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Alexion Pharmaceuticals’ earnings, with the highest sales estimate coming in at $887.00 million and the lowest estimate coming in at $848.22 million. Alexion Pharmaceuticals posted sales of $798.52 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.5%. The business is scheduled to report its next earnings results before the market opens on Thursday, October 26th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year sales of $866.57 million for the current financial year, with estimates ranging from $3.42 billion to $3.59 billion. For the next financial year, analysts expect that the company will post sales of $4.05 billion per share, with estimates ranging from $3.92 billion to $4.25 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. During the same period in the previous year, the business posted $1.13 EPS. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year.

Several research analysts have recently commented on ALXN shares. Leerink Swann reaffirmed an “outperform” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, June 22nd. Robert W. Baird reaffirmed a “neutral” rating and issued a $145.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, June 26th. UBS AG reaffirmed a “buy” rating and issued a $142.00 price objective (up previously from $140.00) on shares of Alexion Pharmaceuticals in a research note on Monday, June 26th. Cowen and Company reaffirmed an “outperform” rating and issued a $122.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, July 3rd. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $154.56.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded down 1.03% during midday trading on Tuesday, reaching $139.02. The company had a trading volume of 2,079,611 shares. The company has a 50 day moving average of $142.43 and a 200 day moving average of $127.67. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The firm has a market capitalization of $31.03 billion, a price-to-earnings ratio of 60.29 and a beta of 1.39.

In other news, EVP Julie O’neill sold 4,375 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total value of $636,300.00. Following the completion of the transaction, the executive vice president now owns 26,092 shares in the company, valued at approximately $3,794,820.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the transaction, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,190 shares of company stock valued at $2,433,669. Company insiders own 4.35% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of ALXN. Guardian Life Insurance Co. of America boosted its holdings in Alexion Pharmaceuticals by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 6 shares during the period. Meeder Asset Management Inc. purchased a new position in Alexion Pharmaceuticals during the 1st quarter valued at $111,000. Fiduciary Trust Co. purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at $111,000. Huntington National Bank boosted its holdings in Alexion Pharmaceuticals by 1,084.6% during the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 987 shares during the period. Finally, Penserra Capital Management LLC boosted its holdings in Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 144 shares during the period. Institutional investors own 94.25% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Expected to Post Quarterly Sales of $866.57 Million” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-expected-to-post-quarterly-sales-of-866-57-million/1644318.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.